Pathogenic role of HMGB1 in SARS?

Med Hypotheses. 2004;63(4):691-5. doi: 10.1016/j.mehy.2004.01.037.

Abstract

High mobility group box 1 protein (HMGB1) is released by necrotic cells or activated macrophages/monocytes, and functions as a late mediator of lethal systemic and local pulmonary inflammation. Passive immunization with anti-HMGB1 antibodies confers significant protection against lethal endotoxemia, sepsis, and acute lung injury, even when antibodies are administered after the onset of these diseases. In light of observations that three Chinese herbal formulations recommended for treatment of severe acute respiratory syndrome (SARS) specifically inhibited the release of HMGB1 from innate immune cells, we hypothesize that HMGB1 might occupy a pathogenic role in SARS by mediating an injurious pulmonary inflammatory response.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Clinical Trials as Topic
  • Drugs, Chinese Herbal / therapeutic use*
  • Evidence-Based Medicine
  • HMGB1 Protein / immunology*
  • Humans
  • Models, Immunological*
  • Pneumonia / drug therapy
  • Pneumonia / immunology*
  • Severe Acute Respiratory Syndrome / drug therapy*
  • Severe Acute Respiratory Syndrome / immunology*
  • Treatment Outcome

Substances

  • Drugs, Chinese Herbal
  • HMGB1 Protein